The cofounder and chief executive officer of NKILT Therapeutics discussed unique advantages of the CIR platform.
Raphaël G. Ognar
Advertisement
Articles by Raphaël G. Ognar
The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.
Raphaël G. Ognar, chief executive officer and co-founder of NKILT Therapeutics, discussed approaches to help increase patient access to cell therapies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
2
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
3
Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy
4
Quarter Century Update: Platform Approaches and Industry Investment
5
